Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cephalexin Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.98 |
| ▸ | MAPT | P10636 | 7/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.98 |
| ▸ | SLC15A2 | Q16348 | 3/20 | 0.98 |
| ▸ | HPGD | P15428 | 3/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.98 |
| ▸ | BLM | P54132 | 2/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.98 |
| ▸ | HTR2B | P41595 | 1/20 | 0.98 |
| ▸ | MEN1 | O00255 | 4/20 | 0.83 |
| ▸ | LMNA | P02545 | 2/20 | 0.83 |
| ▸ | ESR1 | P03372 | 1/20 | 0.83 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.83 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cephalexin Anhydrous SCHEMBL20657431 | 1.00 | HSD17B10 (0.98) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL6663545 | 0.99 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL2224252 | 0.99 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL10925361 | 0.99 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL6663551 | 0.99 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL2961 | 0.99 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL10713860 | 0.99 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL20703090 | 0.99 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL11579781 | 0.99 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL12961263 | 0.99 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12274830-B2 | Nitric oxide inhalation therapy for infants with bronchiolitis | BEYOND AIR LTD (IL) | 2025-04-15 | — | — | US | claimed |
| US-20240173512-A1 | METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS | STREETERVILLE CAPITAL, LLC | 2024-05-30 | — | — | US | claimed |
| CN-117777162-A | Method for refining sodium cefradium by one-step method | 福安药业集团重庆博圣制药有限公司 | 2024-03-29 | — | — | CN | claimed |
| US-11890421-B2 | Methods for potentiating antimicrobial agents | BEYOND AIR LTD (IL) | 2024-02-06 | — | — | US | claimed |
| CN-115043853-A | Preparation method of cefalexin sodium | 齐鲁晟华制药有限公司 | 2022-09-13 | — | — | CN | claimed |
| US-20200246573-A1 | NITRIC OXIDE INHALATION THERAPY FOR INFANTS WITH BRONCHIOLITIS | STREETERVILLE CAPITAL, LLC | 2020-08-06 | — | — | US | claimed |
| US-9499587-B2 | Gamma-AApeptides with potent and broad-spectrum antimicrobial activity | UNIVERSITY OF SOUTH FLORIDA (US) | 2016-11-22 | — | — | US | claimed |
| US-20150274782-A1 | GAMMA-AAPEPTIDES WITH POTENT AND BROAD-SPECTRUM ANTIMICROBIAL ACTIVITY | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-10-01 | — | — | US | claimed |
| WO-2013112548-A1 | GAMMA-AAPEPTIDES WITH POTENT AND BROAD-SPECTRUM ANTIMICROBIAL ACTIVITY | UNIVERSITY OF SOUTH FLORIDA (US) | 2013-08-01 | — | — | WO | claimed |
| US-20260144751-A1 | LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOF | PHARMOSA BIOPHARM INC. (TW) | 2026-05-28 | — | — | US | disclosed |
| US-12551437-B2 | Liposome compositions comprising weak acid drugs and uses thereof | PHARMOSA BIOPHARM INC. (TW) | 2026-02-17 | — | — | US | disclosed |
| US-20250241856-A1 | PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE OF WEAK ACID DRUGS AND USES THEREOF | PHARMOSA BIOPHARM INC. (TW) | 2025-07-31 | — | — | US | disclosed |
| US-20250144026-A1 | LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOF | PHARMOSA BIOPHARM INC. (TW) | 2025-05-08 | — | — | US | disclosed |
| EP-4548975-A2 | NITRIC OXIDE INHALATION THERAPY FOR INFANTS WITH BRONCHIOLITIS | Beyond Air Ltd (IL) | 2025-05-07 | — | — | EP | disclosed |
| US-4410522-A | BACTERICIDES | TOYAMA CHEMICAL CO., LTD. (JP) | 1983-10-18 | — | — | US | disclosed |
| US-4327097-A | BACTERICIDES FOR MAMMALS | TOYAMA CHEMICAL CO., LTD. (JP) | 1982-04-27 | — | — | US | disclosed |
| US-4125716-A | BACTERICIDE | BRISTOL-MYERS COMPANY (US) | 1978-11-14 | — | — | US | disclosed |
| US-4112090-A | BACTERICIDE | TOYAMA CHEMICAL CO., LTD. (JP) | 1978-09-05 | — | — | US | disclosed |
| US-4103008-A | ANTIBIOTICS | TOSHIYASU ISHIMARU | 1978-07-25 | — | — | US | disclosed |
| US-3948903-A | Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins | PARKE, DAVIS & COMPANY (US) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144751-A1 | LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOF | LIPA, NSF, SLC26A3 | HSD17B10 3168/4885MAPT 3202/4885ALDH1A1 2593/4885 |
| US-20150274782-A1 | GAMMA-AAPEPTIDES WITH POTENT AND BROAD-SPECTRUM ANTIMICROBIAL ACTIVITY | ANPEP, DNPEP, ENPEP | HSD17B10 1858/4885MAPT 3150/4885ALDH1A1 2713/4885 |
| US-12551437-B2 | Liposome compositions comprising weak acid drugs and uses thereof | SLC26A3, LIPA, NSF | HSD17B10 3527/4885MAPT 3345/4885ALDH1A1 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.